Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.

Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, Stempora L, Hammond C, Wouters A, Mojcik CF, Cheng J, Collinge M, Jesson MI, Hazra A, Biswas P, Lan S, Clark JD, Hodge JA.

Clin Immunol. 2018 Jun;191:10-20. doi: 10.1016/j.clim.2018.03.002. Epub 2018 Mar 5.

2.

Mechanistic investigations of test article-induced pancreatic toxicity at the endocrine-exocrine interface in the rat.

Brenneman KA, Ramaiah SK, Rohde CM, Messing DM, O'Neil SP, Gauthier LM, Stewart ZS, Mantena SR, Shevlin KM, Leonard CG, Sokolowski SA, Lin H, Carraher DC, Jesson MI, Tomlinson L, Zhan Y, Bobrowski WF, Bailey SA, Vogel WM, Morris DL, Whiteley LO, Davis JW 2nd.

Toxicol Pathol. 2014 Jan;42(1):229-42. doi: 10.1177/0192623313508851. Epub 2013 Nov 13.

PMID:
24226507
3.

Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.

Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, Kishore N.

J Pharmacol Exp Ther. 2014 Jan;348(1):165-73. doi: 10.1124/jpet.113.209304. Epub 2013 Nov 11.

PMID:
24218541
4.

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, Zhan Y, Bollinger CS, Bansal PN, Wellen JW, Wilkie DP, Bailey SA, Symanowicz PT, Hegen M, Head RD, Kishore N, Mbalaviele G, Meyer DM.

Arthritis Rheum. 2012 Nov;64(11):3531-42. doi: 10.1002/art.34649.

5.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ.

J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.

6.

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.

Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL.

J Inflamm (Lond). 2010 Aug 11;7:41. doi: 10.1186/1476-9255-7-41.

7.

Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse.

LaBranche TP, Hickman-Brecks CL, Meyer DM, Storer CE, Jesson MI, Shevlin KM, Happa FA, Barve RA, Weiss DJ, Minnerly JC, Racz JL, Allen PM.

Am J Pathol. 2010 Sep;177(3):1388-96. doi: 10.2353/ajpath.2010.100195. Epub 2010 Aug 9.

8.
9.

Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies.

Jones B, Adams S, Miller GT, Jesson MI, Watanabe T, Wallner BP.

Blood. 2003 Sep 1;102(5):1641-8. Epub 2003 May 8.

10.

The immune response to soluble D10 TCR: analysis of antibody and T cell responses.

Jesson MI, McKeever U, Khandekar S, Newcomb J, Naylor J, Gregory P, Brauer P, Bettencourt B, Banerji J, Jones B.

Int Immunol. 1998 Jan;10(1):27-35.

PMID:
9488153
11.

On the nature of the mutation in the nude rat.

Jones B, Jesson MI.

Trends Genet. 1995 Jul;11(7):257-8. No abstract available.

PMID:
7482772
13.

Characterization of the DNA-DNA cross-linking activity of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin.

Jesson MI, Johnston JB, Robotham E, Begleiter A.

Cancer Res. 1989 Dec 15;49(24 Pt 1):7031-6.

14.

Supplemental Content

Loading ...
Support Center